Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Canagliflozin Tablets

Function:
This product is mainly used to treat type 2 diabetes and can be used in combination with metformin and metformin/sulfonylurea drugs.

Dosage:
The recommended starting dose of this product is 100 mg once a day, before the first meal of the day. For patients who tolerate a dose of 100 mg once daily, have an estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2, and require additional glycemic control, the dose may be increased to 300 mg once daily. Please follow your doctor’s advice for details. In patients who are volume depleted, it is recommended to correct the condition before initiating treatment with this product. Patients with Renal Impairment: It is recommended to evaluate renal function before initiating treatment with this product and periodically after starting treatment. No dose adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m). For patients with moderate renal impairment (eGFR ≥45 to <60mL/min/1.73m), the dose of this product is limited to 100 mg once daily. When eGFR continues to be lower than 45mL/min/1.73m, the use of this product is not recommended. Patients with eGFR lower than 30mL/min/1.73m are prohibited from using this product. Patients with Hepatic Impairment: No dose adjustment is required in patients with mild to moderate hepatic impairment. There are currently no I clinical studies in patients with severe hepatic impairment, so patients with severe hepatic impairment are not recommended to use this product. Concomitant use with UDP-glucuronyltransferase (UGT) inducers If a UGT inducer (e.g., rifampicin, phenytoin, phenobarbital, ritonavir) is used concomitantly with this product, currently tolerated For patients with a once-daily dose of 100 mg of this product, eGFR ≥ 60 mL/min/1.73 m, and who require additional blood glucose control, an increase in dose to 300 mg once a day may be considered. For patients with an eGFR ≥45 to <60mL/min/1.73m who are concurrently receiving a UGT inducer, another antidiabetic agent may be considered. Note: The same medicines produced by different manufacturers may have inconsistent instructions. If you find any inconsistency in the instructions before taking the medicine, please consult your doctor or pharmacist in time. Drug contraindications: Disabled if allergic to this product Related dosage forms: tablet

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.